Senate DTC hearing
Senate Commerce/Consumer Affairs Subcommittee DTC advertising hearing postponed until July 24. The committee had rescheduled the hearing for July 18 after being delayed May 22 due to floor votes. The witness list will remain the same as the May hearing; FDA's Division of Drug Marketing, Advertising & Communications and the Pharmaceutical Research & Manufacturers of America are among those testifying (1"The Pink Sheet" May 28, p. 9)
You may also be interested in...
FDA regulation helps ensure that direct-to-consumer ads are the most reliable prescription drug information available, the Pharmaceutical Research & Manufacturers of America maintains.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials